Impact of the JAK Inhibitor Approval Delays

Episode 30,  Sep 02, 2021, 04:00 AM

This episode takes a deep dive in the recent delay in approval for multiple JAK inhibitor drugs for treatment of inflammatory skin conditions such as psoriasis and atopic dermatitis. Mark Lebwohl, MD, discusses the impact of the delay, as well as the benefits of JAK inhibitors for inflammatory skin diseases, and an outlook for the future of this drug class.